David Dolphin is Professor Emeritus with the University of British Columbia. He has administrative and research experience in industry, universities and non-governmental organizations. As the Vice-President Technology Development at Quadra Logic Technologies, he was instrumental in the discovery, development and commercialization of Visudyne, which has saved the vision of hundreds of thousands of people afflicted with "wet" age-related macular degeneration. He has served on numerous boards and is currently the Chair of Genome British Columbia. He has received several awards, including the Prix Galien in 2002 (along with Julia Levy). The Prix Galien has been described by the international pharmaceutical industry as the industry's equivalent of the Nobel Prize and the highest accolade for pharmaceutical research he is also a fellow of the Royal Society (London). He is an officer of the Order of Canada; a Director on the Alberta Innovates Health Solutions Board and Chair of the Board of the Center for Drug Research and Development.